Evidence map›Paper›PMID 34910776›Full record

ArticlePloS one2021

Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania.

Herry Mapesi, James Okuma, Fabian Franzeck, Herieth Ismael Wilson, Elizabeth Senkoro, Theonestina Byakuzana, Robert Ndege, Fiona Vanobberghen, Tracy Renée Glass, Manuel Battegay and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Herry MapesiIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.ORCID 0000-0001-7753-464X
James OkumaSwiss Tropical and Public Health Institute, Basel, Switzerland.
Fabian FranzeckDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Herieth Ismael WilsonIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Elizabeth SenkoroIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Theonestina ByakuzanaIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Robert NdegeIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Fiona VanobberghenSwiss Tropical and Public Health Institute, Basel, Switzerland.
Tracy Renée GlassSwiss Tropical and Public Health Institute, Basel, Switzerland.
Manuel BattegayUniversity of Basel, Basel, Switzerland.
Maja WeisserIfakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Daniel Henry ParisSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0003-4743-5987
KIULARCO Study Group
Ifakara Health Institute · TZSwiss Tropical and Public Health Institute · CHUniversity Hospital of Basel · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRitonavir-boosted protease inhibitors (bPI) in people living with HIV (PLWH) have been associated with renal impairment. Limited data are available from rural sub-Saharan Africa.

methodsUsing data from the Kilombero and Ulanga Antiretroviral Cohort Study (KIULARCO) in rural Tanzania from 2005-01/2020, we assessed the prevalence of renal impairment (estimated glomerular filtration rate <60 mL/min/1.73m2) at the time of switch from first-line antiretroviral treatment (ART) to bPI-regimen and the incidence of renal impairment on bPI. We assessed risk factors for renal impairment using logistic and Cox regression models.

resultsRenal impairment was present in 52/687 PLWH (7.6%) at the switch to bPI. Among 556 participants with normal kidney function at switch, 41 (7.4%) developed renal impairment after a median time of 3.5 (IQR 1.6-5.1) years (incidence 22/1,000 person-years (95%CI 16.1-29.8)). Factors associated with renal impairment at switch were older age (adjusted odds ratio (aOR) 1.55 per 10 years; 95%CI 1.15-2.11), body mass index (BMI) <18.5 kg/m2 (aOR 2.80 versus ≥18kg/m2; 95%CI 1.28-6.14) and arterial hypertension (aOR 2.33; 95%CI 1.03-5.28). The risk of renal impairment was lower with increased duration of ART use (aOR 0.78 per one-year increase; 95%CI 0.67-0.91). The renal impairment incidence under bPI was associated with older age (adjusted hazard ratio 2.01 per 10 years; 95%CI 1.46-2.78).

conclusionsIn PLWH in rural sub-Saharan Africa, prevalence and incidence of renal impairment among those who were switched from first-line to bPI-regimens were high. We found associations between renal impairment and older age, arterial hypertension, low BMI and time on ART.

Indexed as

AdultAnti-HIV AgentsAnti-Retroviral AgentsCohort StudiesFemaleGlomerular Filtration RateHIV-1HIV InfectionsHIV Protease InhibitorsHumansIncidenceMaleMiddle AgedPrevalenceProspective StudiesRenal InsufficiencyAnti-HIV AgentsAnti-Retroviral AgentsHIV Protease Inhibitors

Identifiers

PMID34910776
PMCPMC8673654
OpenAlexW4200256696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.